Heska Corporation

Fort Collins, CO 80525

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $0.0
First Award Date 09/30/89
Most Recent Award Date 04/01/96

Key Personnel

Last Name Name Awards Contact
Popiel Irene Popiel 4
Dale Beverly Dale 1
Xiong Cheng Xiong 3

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/96 - 03/31/97

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/95 - 03/31/96

DESCRIPTION: (Adapted from applicant's abstract) Immunity to wild type Toxoplasma gondii may be induced in cats by bradyzoites of an oocyst negative strain, T-263. A feline vaccine based on this premise would serve to reduce toxoplasmosis in humans by reducing environmental oocyst contamination. Successful commercialization of a vaccine ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/94 - 06/30/95

DESCRIPTION: (Adapted from the applicant's abstract) A P30, the major surface antigen of the T. gondii tachyzoite stage, has been isolated and shown to protect mice from a virulent T. gondii challenge. In Phase I of this project, the genomic DNA encoding P30 has been subcloned into Sindbis virus vectors and expressed in baby hamster kidney...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/93 - 06/30/94

DESCRIPTION: (Adapted from the applicant's abstract) A P30, the major surface antigen of the T. gondii tachyzoite stage, has been isolated and shown to protect mice from a virulent T. gondii challenge. In Phase I of this project, the genomic DNA encoding P30 has been subcloned into Sindbis virus vectors and expressed in baby hamster kidney...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/93 - 12/14/93

Toxoplasma gondii strain T-263 is an oocyst negative genetic mutant that induces immuni in cats to wild type strains when tissue cysts or bradyzoites are administered orally. The vaccine potential of T-263 has been proven in two separate efficacy studies. The stability of the oocyst-negative phenotype of T-263 has been demonstrated. Use of thi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/92 - 03/31/93

Toxoplasma gondii strain T-263 is an oocyst negative genetic mutant that induces immunity in cats to wild type strains when tissue cysts or bradyzoites are administered orally. The vaccine potential of T-263 has been proven in two separate efficacy studies. Use of this feline vaccine will reduce oocyst contamination of homes and surroundings t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/91 - 06/30/91

DESCRIPTION (Adapted from applicant's abstract): P30, the major surface antigen of the Toxoplasma gondii tachyzoite stage, has been isolated from the parasite and shown to protect mice from a virulent T. gondii challenge. The cDNA encoding P30 had been cloned and expressed in E. coli, producing recombinant protein that was poorly recognized by ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/89 - 03/31/90

The specific aim of this proposal is to improve survival and proliferative ability of tick cell lines. Drawing upon recent improvements in the tissue culture of insect cells that have led to the commercial scale-up of recombinant proteins expressed in insect cells, nutritional, physiological, biochemical, and biophysical parameters for optimum t...